S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
NVDA   294.07 (-4.74%)
BABA   212.58 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.31%)
TSLA   901.00 (+0.18%)
AMD   56.76 (-0.91%)
T   38.53 (-0.21%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.99%)
BAC   34.37 (-1.38%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
NVDA   294.07 (-4.74%)
BABA   212.58 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.31%)
TSLA   901.00 (+0.18%)
AMD   56.76 (-0.91%)
T   38.53 (-0.21%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.99%)
BAC   34.37 (-1.38%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
NVDA   294.07 (-4.74%)
BABA   212.58 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.31%)
TSLA   901.00 (+0.18%)
AMD   56.76 (-0.91%)
T   38.53 (-0.21%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.99%)
BAC   34.37 (-1.38%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
NVDA   294.07 (-4.74%)
BABA   212.58 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.31%)
TSLA   901.00 (+0.18%)
AMD   56.76 (-0.91%)
T   38.53 (-0.21%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.99%)
BAC   34.37 (-1.38%)
Log in

NASDAQ:MBIO - Mustang Bio Stock Price, Forecast & News

$3.96
+0.07 (+1.80 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$3.85
Now: $3.96
$4.10
50-Day Range
$3.67
MA: $3.96
$4.52
52-Week Range
$2.51
Now: $3.96
$10.20
Volume557,253 shs
Average Volume202,213 shs
Market Capitalization$160.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MBIO
CUSIPN/A
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.32 per share

Profitability

Net Income$-30,660,000.00

Miscellaneous

Employees38
Market Cap$160.62 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive MBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.


Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions

What is Mustang Bio's stock symbol?

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

How were Mustang Bio's earnings last quarter?

Mustang Bio Inc (NASDAQ:MBIO) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. View Mustang Bio's Earnings History.

When is Mustang Bio's next earnings date?

Mustang Bio is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Mustang Bio.

What price target have analysts set for MBIO?

3 analysts have issued twelve-month price objectives for Mustang Bio's stock. Their forecasts range from $7.00 to $18.00. On average, they anticipate Mustang Bio's share price to reach $10.67 in the next year. This suggests a possible upside of 169.4% from the stock's current price. View Analyst Price Targets for Mustang Bio.

What is the consensus analysts' recommendation for Mustang Bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mustang Bio.

Has Mustang Bio been receiving favorable news coverage?

Media headlines about MBIO stock have been trending somewhat positive recently, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mustang Bio earned a news impact score of 1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the company's share price in the immediate future. View News Stories for Mustang Bio.

Who are some of Mustang Bio's key competitors?

What other stocks do shareholders of Mustang Bio own?

Who are Mustang Bio's key executives?

Mustang Bio's management team includes the folowing people:
  • Mr. Michael S. Weiss, Exec. Chairman (Age 53)
  • Dr. Manuel Litchman, Pres, CEO & Director (Age 65)
  • Mr. David Jay Horin CPA, Interim Chief Financial Officer (Age 51)
  • Mr. Brian K. Achenbach, VP of Fin. & Corp. Controller (Age 54)
  • Dr. Knut Niss, Chief Technology Officer

Who are Mustang Bio's major shareholders?

Mustang Bio's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.89%), State Street Corp (1.22%), Geode Capital Management LLC (0.95%), Ikarian Capital LLC (0.80%), Parkman Healthcare Partners LLC (0.75%) and Oxford Asset Management LLP (0.56%). View Institutional Ownership Trends for Mustang Bio.

Which institutional investors are selling Mustang Bio stock?

MBIO stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC and Bank of America Corp DE. View Insider Buying and Selling for Mustang Bio.

Which institutional investors are buying Mustang Bio stock?

MBIO stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Parkman Healthcare Partners LLC, Oxford Asset Management LLP, Renaissance Technologies LLC, National Asset Management Inc., FNY Investment Advisers LLC, UBS Group AG and State Street Corp. View Insider Buying and Selling for Mustang Bio.

How do I buy shares of Mustang Bio?

Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mustang Bio's stock price today?

One share of MBIO stock can currently be purchased for approximately $3.96.

How big of a company is Mustang Bio?

Mustang Bio has a market capitalization of $160.62 million. The company earns $-30,660,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Mustang Bio employs 38 workers across the globe.View Additional Information About Mustang Bio.

What is Mustang Bio's official website?

The official website for Mustang Bio is http://www.mustangbio.com/.

How can I contact Mustang Bio?

Mustang Bio's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Mustang Bio (NASDAQ MBIO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  280
MarketBeat's community ratings are surveys of what our community members think about Mustang Bio and other stocks. Vote "Outperform" if you believe MBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel